1. Home
  2. ENSC vs NBY Comparison

ENSC vs NBY Comparison

Compare ENSC & NBY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENSC
  • NBY
  • Stock Information
  • Founded
  • ENSC 2003
  • NBY 2000
  • Country
  • ENSC United States
  • NBY United States
  • Employees
  • ENSC N/A
  • NBY N/A
  • Industry
  • ENSC Biotechnology: Pharmaceutical Preparations
  • NBY
  • Sector
  • ENSC Health Care
  • NBY
  • Exchange
  • ENSC Nasdaq
  • NBY Nasdaq
  • Market Cap
  • ENSC 6.4M
  • NBY 6.3M
  • IPO Year
  • ENSC N/A
  • NBY 2007
  • Fundamental
  • Price
  • ENSC $1.68
  • NBY $0.95
  • Analyst Decision
  • ENSC
  • NBY
  • Analyst Count
  • ENSC 0
  • NBY 0
  • Target Price
  • ENSC N/A
  • NBY N/A
  • AVG Volume (30 Days)
  • ENSC 79.2K
  • NBY 145.1K
  • Earning Date
  • ENSC 11-14-2025
  • NBY 11-07-2025
  • Dividend Yield
  • ENSC N/A
  • NBY N/A
  • EPS Growth
  • ENSC N/A
  • NBY N/A
  • EPS
  • ENSC N/A
  • NBY 0.47
  • Revenue
  • ENSC $4,487,973.00
  • NBY $10,302,000.00
  • Revenue This Year
  • ENSC N/A
  • NBY $23.91
  • Revenue Next Year
  • ENSC N/A
  • NBY $32.05
  • P/E Ratio
  • ENSC N/A
  • NBY $34.97
  • Revenue Growth
  • ENSC 1.51
  • NBY 390.34
  • 52 Week Low
  • ENSC $1.53
  • NBY $0.46
  • 52 Week High
  • ENSC $10.96
  • NBY $4.44
  • Technical
  • Relative Strength Index (RSI)
  • ENSC 30.16
  • NBY 39.91
  • Support Level
  • ENSC $1.53
  • NBY $0.86
  • Resistance Level
  • ENSC $2.17
  • NBY $1.11
  • Average True Range (ATR)
  • ENSC 0.14
  • NBY 0.09
  • MACD
  • ENSC -0.04
  • NBY -0.00
  • Stochastic Oscillator
  • ENSC 24.81
  • NBY 32.42

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

About NBY NovaBay Pharmaceuticals Inc.

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.

Share on Social Networks: